Skip to content
Open access · CC-BY via OpenAlex

Biological age measured by DNA methylation clocks and frailty: a systematic review and meta-analysis

Jian Hua Tay, Duarte Gabriel Moleiro Barros, Weilan Wang, Vanessa Kristina Wazny, Andrea Britta Maier

The Lancet Healthy Longevity · 2025 · ▲ 14 citations

Abstract

Background Frailty is an age-related condition characterised by multisystem physiological decline, which increases vulnerability to adverse outcomes. Biomarkers of ageing might identify individuals at risk and enable early interventions. This systematic review and meta-analysis aimed to examine cross-sectional and longitudinal associations between DNA methylation-based biological age metrics (eg, DNA methylation age, epigenetic-age acceleration [EAA], and age deviation) and frailty. Methods In a systematic search of six databases (Embase, Cochrane Central Register of Controlled Trials, PubMed, Ovid, Scopus, and Web of Science) from Jan 1, 2011, to June 6, 2025, we identified population-based cohort studies reporting associations between DNA methylation age, EAA, or age deviation and frailty from general or disease-specific populations with a control group. Risk of bias was assessed using an adapted Newcastle–Ottawa Scale. Random-effects meta-analyses with Hartung–Knapp adjustments were performed on standardised β coefficients and SEs. Publication bias, influence, and sensitivity analyses were conducted. Findings From 34 437 records screened, 24 studies met the inclusion criteria (17 cross-sectional studies, one longitudinal study, and six studies that were both cross-sectional and longitudinal), encompassing 28 325 participants (14 757 [52·1%] female; median of mean age 65·2 years [IQR 62·2–69·4]). DNA methylation age and age deviation showed no association with frailty. In cross-sectional meta-analyses, higher Hannum EAA (nine studies; n=11 162; standardised β coefficient 0·06 [95% CI 0·02–0·09], I 2 =71·4%), PhenoAge EAA (eight studies; n=10 371; 0·07 [0·03–0·11], I 2 =81·7%), GrimAge EAA (eight studies; n=10 371; 0·11 [0·06–0·15], I 2 =90·5%), and pace of ageing (five studies; n=7895; 0·10 [0·01–0·19], I 2 =91·0%) were significantly associated with higher frailty. In longitudinal meta-analyses, higher GrimAge EAA (five studies; n=6143; 0·02 [0·00–0·05], I 2 =46·0%, p=0·0481) was significantly associated with increases in frailty, whereas PhenoAge EAA and pace of ageing were not significantly associated with frailty. Interpretation Higher GrimAge EAA is consistently associated with higher frailty. Future research should focus on developing and validating DNA methylation clocks that integrate molecular surrogates of health risk and are specifically trained to predict frailty in large, harmonised, longitudinal cohorts, enabling their translation into clinical practice. Funding National University of Singapore.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1016/j.lanhl.2025.100773
Canonical
link ↗
Fetched
2026-10-14 MST

Cite this

APA
Tay, J.H., Barros, D.G.M., Wang, W., Wazny, V.K., &amp; Maier, A.B. (2025). Biological age measured by DNA methylation clocks and frailty: a systematic review and meta-analysis. <em>The Lancet Healthy Longevity</em>. https://doi.org/10.1016/j.lanhl.2025.100773
Vancouver
Tay JH, Barros DGM, Wang W, Wazny VK, Maier AB. Biological age measured by DNA methylation clocks and frailty: a systematic review and meta-analysis. The Lancet Healthy Longevity. 2025. doi:10.1016/j.lanhl.2025.100773.
BibTeX
@article{jian2025Biolog, title = {Biological age measured by DNA methylation clocks and frailty: a systematic review and meta-analysis}, author = {Jian Hua Tay and Duarte Gabriel Moleiro Barros and Weilan Wang and Vanessa Kristina Wazny and Andrea Britta Maier}, journal = {The Lancet Healthy Longevity}, year = {2025}, doi = {10.1016/j.lanhl.2025.100773}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings